Innovation Pharmaceuticals Inc (IPIX)

[Cognition]

IPIX just announced an almost 90% reduction in viral load in the lungs with the lowest dose given by the Lab. That dose was equivalent to HALF the dose given in a previous successful phase 2 study IPIX did comparing Brilacidin to Daptomycin. That phase 2 study wasn’t done in petri dish. It was done in actual human beings. There was zero serious adverse effects in that study. This means based on its MOA Brilacidin will be safe and effective not just against Covid-19 but ALL viruses that have a protective membrane surrounding it. For those who have the ability to realize it the news we’ve been waiting for has already come. We now wait for the rest of the world to catch up.